Durvalumab 500mg/10ml solution for infusion vials
NHS hospitals in England used £120,927,215 of indicative cost of Durvalumab 500mg/10ml solution for infusion vials in the 12 months to April 2026, about 0.5% of all hospital medicines spend. That is up 34.6% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Durvalumab 500mg/10ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to April 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Durvalumab 500mg/10ml solution for infusion vials most
By indicative cost over the 12 months to April 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| The Clatterbridge Cancer Centre Nhs Ft | £10,902,186 |
| The Royal Marsden Nhs Foundation Trust | £6,034,302 |
| The Christie Nhs Foundation Trust | £3,795,174 |
| United Lincolnshire Hospitals Nhs Trust | £3,627,486 |
| Guy's & St Thomas' Nhs Foundation Trust | £3,442,536 |
| Nottingham University Hospitals Trust | £3,117,024 |
| Univ Hpl B/Ham Nhs Foundation Trust | £3,112,092 |
| Imperial College Healthcare Nhs Trust | £3,092,364 |
| Royal Free London Nhs Foundation Trust | £3,047,976 |
| Royal Surrey County Hosp Nhs Found Trust | £2,462,794 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.